I have to consider AZN as a much less sexier but much safer potential China play.
I would suggest ABT for that role. ABT has a big business in China not only in pharmaceuticals (branded generics), but also in medical devices, diagnostics, and nutrition products.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”